Impact of ICCAN on Cancer Treatment Completion and Quality of Life

Inclusion Criteria

• •fluent in English, Spanish, or Mandarin
• •between the ages of 21-80 years old
• •cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
• •scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
• •planning on remaining in the area for at least 1 year
• •Has an MD or DO degree
• •Is the treating physician providing care to a patient enrolled to the study
• •Is 18 - 85 years of age
• •Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
• •Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
• •Is treated in the NY metropolitan area
• •Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income \< 200% of federal poverty level)
• •Has English or Spanish proficiency
• •Agrees to be audio-recorded
• •Is 18 - 85 years of age
• •Has stage II-III TNBC
• •Treated at MSK Manhattan or OneMSK regional sites
• •Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income \< 200% of federal poverty level)
• •Has English or Spanish proficiency
• •Agrees to be audio-recorded
• •ICCAN-IO process evaluation study team participants only:
• •Staff member who serves as an Access Facilitator
• •Agrees to be audio-recorded
• •Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
• •Participants or family members who are participating in MSK IHCD studies related to social determinants of health
• •Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
• •Participants or family members who are participating in MSK IHCD studies related to social determinants of health